Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. - Carter, C. A.; Rajan, A.; Keen, C.; Szabo, E.; Khozin, S.; Thomas, A.; Brzezniak, C.; Guha, U.; Doyle, L. A.; Steinberg, S. M.; Xi, L.; Raffeld, M.; et al. (Annals of Oncology, 2016)